Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4.
|
26332365 |
2016 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
β-catenin protein expression was, however, detected in the membrane and cytoplasm of 69.6% (32/46) of the osteosarcomas. c-myc protein expression was detected in only 47.8% (22/46) and cyclin D1 protein expression in 52.2% (24/46) of osteosarcoma samples.
|
24942472 |
2014 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After SOST gene silencing, the mRNA and protein expression levels of Wnt1, β-catenin, C-Myc, Cyclin D1, and MMP-7 in osteosarcoma cells and β-catenin protein expression levels in the nucleus and cytoplasm were significantly elevated.
|
28246931 |
2017 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, these data provide evidence that the repression of syndecan-2 by Wnt/β-catenin/TCF signaling contributes to the resistance of osteosarcoma cells to doxorubicin and suggest that TCF inhibition may represent a novel therapeutic strategy in osteosarcoma.
|
22550000 |
2012 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
And β-catenin may be a potential therapeutic target as well as a significant prognostic marker for osteosarcoma patients in clinic.
|
29497056 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Attenuation of Wnt/β-catenin activity by tankyrase inhibitors is an appealing strategy in treatment of OS.
|
24403055 |
2014 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AWPPH enhances FZD7-mediated activation of Wnt/β-catenin by sponging miR-93-3p to promote OS progression.
|
31092328 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our study indicated that macrophage-derived CCL18 promotes OS proliferation and metastasis via the EP300/UCA1/Wnt/β-catenin pathway and that CCL18 may be used as a prognostic marker and therapeutic target of OS.
|
30426155 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistently, the expression level of β-catenin protein correlated with the invasiveness of OS, as evidenced by more intensive β-catenin immunoreactivity in higher grade OS samples.
|
23291185 |
2013 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CRY2 knockdown also increased the expression of matrix metalloproteinase (MMP)-2 and β-catenin, and increased OS cell proliferation and migration by inducing cell cycle progression and promoting mitogen-activated protein kinase (MAPK) and Wnt/β-catenin signaling pathways.
|
29879092 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression rates driven by osteoblast- specific fragments from the collagen1A1-promoter, the human Osteocalcin-promoter, the bone-sialoprotein promoter and the beta-catenin promoter depending on vitamin supplementation were analysed in five OS cell lines, in normal lung fibroblasts and in a non-osteoblastic prostate cancer cell line (LNCaP) by dual luciferase assays.
|
15375610 |
2004 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we revealed that silybin inhibited OS cell viability by altering the protein levels of β-catenin and Runt-related transcription factor 2 (RUNX2) as determined by western blot and immunocytochemistry (ICC).
|
29068478 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, miR-744 induced Wnt/β-catenin pathway and epithelial-mesenchymal transition (EMT) in OS.
|
31452740 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the demethylation of SFRP2 gene appeared to inhibit nuclear retention of a key Wnt signaling factor, β-catenin, in OS cell lines.
|
26628297 |
2016 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher expression of miR-940, β-catenin, and cyclinD1 and lower SFRP1 expression were identified in OS tissues. miR-940 targeted and negatively regulated SFRP1 expression.
|
30324663 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the precise role of T cell factors/lymphoid enhancer-binding factor (TCFs/LEF) family members, which are the major binding complex of β-catenin, in OS is poorly understood.
|
31595984 |
2020 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemically, cadherin-11, N-cadherin, and beta-catenin were expressed at the cell surface of fetal osteoblasts, whereas in osteosarcoma cells, they were expressed only focally or weakly in the cytoplasm.
|
10550312 |
1999 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, 2-ME treatment regulates downstream Wnt signaling, increasing the cytoplasmic levels of β-catenin, and blocking β-catenin-mediated Wnt activation in osteosarcoma cells.
|
27883247 |
2017 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our research verified that suppression of CAT104 exerted significant inhibitory effects on osteosarcoma cell proliferation, migration, and invasion by regulating the expression of miR-381 and downstream ZEB1, as well as JNK and Wnt/β-catenin pathways.
|
29523223 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results showed that TUG1 plays an important role in osteosarcoma development through miRNA-144-3p/EZH2/Wnt/β-catenin pathway.
|
28902349 |
2017 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results supported a model in which the DNA methylation-mediated down-regulation of miR-370 reduced its inhibitory effect on FOXM1, thereby promoting FOXM1-β-catenin interaction and activating the Wnt/β-Catenin signaling pathway in human osteosarcoma cells.
|
28539830 |
2017 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the present study suggested that NOB1 depletion may inhibit osteosarcoma development by increasing E-cadherin and β-catenin expression and, for the first time, indicated the potential of NOB1 as a target in osteosarcoma treatment.
|
24714960 |
2014 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these findings indicate that XRCC6 exerts tumor-promoting effects for OS through β-catenin/Wnt signaling pathway.
|
27455247 |
2016 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, we demonstrate that TWIST decreases osteosarcoma cell survival against cisplatin by decreasing the soluble β-catenin level through a PI3K-dependent manner.
|
23280703 |
2014 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to other tumors, beta-catenin may not play an oncogenic role in osteosarcoma cells.
|
21517265 |
2011 |